IN PHASE 3 TRIALS

CagriSema (Cagrilintide + Semaglutide)

Novo Nordisk's next-generation weight-loss combination, semaglutide plus an amylin analog, in one weekly injection. The Phase 3 numbers are real. They were also less than Wall Street wanted. Both things are true.

The 30-second read

CagriSema is Novo Nordisk's combination of cagrilintide (a long-acting amylin analog) and semaglutide (the GLP-1 in Ozempic and Wegovy) in a single fixed-dose weekly injection. The pitch: stack two complementary appetite-suppressing mechanisms, amylin and GLP-1, for greater weight loss than either alone. The Phase 3 REDEFINE program reported in late 2024 / 2025 that CagriSema produced about 22.7% mean weight loss over 68 weeks. That's meaningful, real, and competitive with tirzepatide. It was also below Novo's previously-guided expectations of about 25%, which moved the stock and reset expectations. Not yet FDA-approved. Submission expected in 2026, potential approval in 2027–28 if the program reads through.

Why this combination is on people's radar

CagriSema represents Novo Nordisk's next move in the GLP-1 weight-loss arms race. Tirzepatide (Mounjaro / Zepbound) outperformed Novo's semaglutide in the SURMOUNT-5 head-to-head trial, 20.2% vs 13.7% over 72 weeks. That gap was big enough that Novo needed a response, and CagriSema is it. The strategy: rather than develop a single-molecule three-receptor agonist (like Eli Lilly's retatrutide), Novo combines its established GLP-1 (semaglutide) with a complementary mechanism (amylin via cagrilintide).

The Phase 3 REDEFINE-1 trial readout in December 2024 was one of the most-anticipated metabolic-medicine readouts of the year. Novo had previously guided to expectations around 25% weight loss. The actual result was about 22.7%, a real, meaningful number that beats every approved weight-loss medication except tirzepatide, and is essentially neck-and-neck with tirzepatide's 22.5% in SURMOUNT-1. But "essentially neck-and-neck with the existing leader" wasn't what Wall Street had priced in. Novo's stock dropped about 20% on the readout. The company's narrative shifted from "next-generation leadership" to "competitive with tirzepatide."

For the actual people who will potentially use CagriSema, the picture is different from the stock-price story. A drug that produces ~23% weight loss over 68 weeks is meaningful weight loss. The competitive question between CagriSema and tirzepatide will likely come down to side-effect profiles, insurance coverage, list prices, and patient-level response variability. Both are good options if approved.

What people are usually trying to do with it

People reading about CagriSema are usually following the obesity-drug development landscape. The clinical question for individuals is similar to other GLP-1-class drugs:

  • Lose meaningful weight that hasn't responded to lifestyle alone
  • Manage type 2 diabetes alongside weight
  • Reduce cardiovascular risk associated with obesity
  • Find an option with a different side-effect profile than tirzepatide or semaglutide alone
  • Add a complementary appetite-suppression mechanism rather than just a higher dose of a GLP-1

What the science actually shows

CagriSema has rigorous Phase 3 data that's still being completed. Plain-English summary:

REDEFINE-1 Phase 3, chronic weight management

Published 2024–2025. CagriSema produced about 22.7% mean weight loss over 68 weeks in adults with overweight or obesity (without diabetes). Below Novo's 25% guidance, comparable to tirzepatide's SURMOUNT-1 number.1

REDEFINE-2, type 2 diabetes

Phase 3 trial in adults with type 2 diabetes and overweight/obesity. Reported A1C improvements and weight reduction; specific magnitude varies by patient subgroup.2

Mechanistic rationale and additivity

Phase 1b/2 data confirmed that cagrilintide + semaglutide produces greater weight loss than either alone, supporting the additive-mechanism hypothesis. Side-effect profile in early data was comparable to semaglutide alone.3

Cardiovascular outcomes (planned/ongoing)

Cardiovascular outcomes trials for CagriSema are part of the broader development program. Outcomes data not yet available.

What hasn't been demonstrated

FDA approval. Long-term real-world tolerability outside trial conditions. Direct head-to-head data versus tirzepatide. Whether the additive mechanism produces a meaningfully different patient-level experience than higher-dose semaglutide alone.

The honest read

What's solid:

CagriSema's Phase 3 data is real and meaningful. ~22.7% mean weight loss over 68 weeks is competitive with the best approved options. The mechanistic rationale (combining amylin and GLP-1) is biologically coherent. The Phase 3 program is rigorous and Novo's regulatory and commercial capabilities are mature.

What's still being worked out:

FDA submission and approval timing. Real-world tolerability. Insurance coverage strategy. How CagriSema will position commercially against tirzepatide and against retatrutide (when retatrutide is eventually approved). Whether it will be priced at a premium versus Wegovy or in line with it.

What's hyped beyond the evidence:

Treating CagriSema as already available, it isn't. "Compounded CagriSema" being marketed online is not the FDA-approved drug (which doesn't yet exist) and isn't operating under any manufacturing oversight. Also: framing the REDEFINE-1 readout as a failure. It wasn't a failure, it was a meaningful clinical result that fell short of Novo's pre-set expectations. Wall Street's reaction shouldn't be the framing patients use to evaluate the drug.

Things to know if you're looking into it

  • Investigational status: CagriSema is in Phase 3. Not FDA-approved. Novo Nordisk has guided to a 2026 FDA submission, with potential approval and launch in 2027–28 if the program reads through.
  • Two peptides in one injection: a fixed-dose combination of cagrilintide and semaglutide in a single weekly subcutaneous shot.
  • Different mechanism stack: CagriSema combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). This is a different combination strategy than tirzepatide's GLP-1 + GIP or retatrutide's GLP-1 + GIP + glucagon.
  • Compounded versions are not the drug: any product marketed as "compounded CagriSema" is not the FDA-approved drug (which doesn't yet exist) and isn't operating under FDA manufacturing oversight.
  • Side-effect profile: Phase 3 data shows GI side effects (nausea, diarrhea) similar to semaglutide alone, not noticeably worse from adding cagrilintide.
  • How it will compete: against tirzepatide and Wegovy primarily. The patient-level differences will likely come down to side effects, insurance, and individual response.
  • Specific dosing schedule, mechanism, and trial detail: all in the "Want to go deeper?" section below.

What people often ask

Is CagriSema approved?

No. As of May 2026, CagriSema is in Phase 3 development. Novo Nordisk has guided to a 2026 FDA submission with potential approval in 2027–28.

Did REDEFINE-1 fail?

No, but Novo's guidance had set expectations around 25% weight loss, and the actual result of about 22.7% missed that bar. The drug still produced meaningful weight loss competitive with tirzepatide. The "disappointment" framing came from financial markets, not from clinical results that wouldn't otherwise have been considered very good.

How does it compare to Zepbound (tirzepatide)?

Phase 3 numbers are essentially in the same range. CagriSema 22.7% in REDEFINE-1, tirzepatide 22.5% in SURMOUNT-1. Direct head-to-head data isn't available. The competition between them once both are approved will depend on side effects, insurance coverage, and individual patient response.

How is it different from just taking semaglutide alone?

The cagrilintide component adds amylin-receptor activity, which suppresses appetite through a different mechanism. Phase 3 showed CagriSema produces more weight loss than semaglutide alone (~22.7% vs ~14.9% for semaglutide 2.4 mg in STEP-1).

Is the side-effect profile worse than semaglutide?

Trial data so far hasn't shown a meaningfully worse side-effect profile from adding cagrilintide to semaglutide, primarily GI symptoms similar to semaglutide alone. The full real-world profile will become clearer post-approval.

Can I get it now?

Through a clinical trial. ClinicalTrials.gov has the active REDEFINE trials searchable. Anything sold as "CagriSema" outside trials isn't the FDA-approved drug, that drug doesn't exist yet.

What about the Novo stock drop?

That's a financial-markets story about pre-set expectations, not a clinical-evidence story about whether the drug works. The drug works. Novo just guided expectations higher than the actual result.

FDA and regulatory status

Status as of May 5, 2026: Investigational. Not FDA-approved. Currently in Phase 3 trials (REDEFINE program) for chronic weight management and for type 2 diabetes. Novo Nordisk has publicly guided to a 2026 FDA submission, with potential approval and launch in 2027–28 if the program reads through. Status updates land here when they happen.

Want to go deeper? Component breakdowns, mechanism, the REDEFINE Phase 3 detail, side effects, and references.

The two components, briefly

Cagrilintide, the amylin component

A long-acting amylin analog by Novo Nordisk. Acts on amylin and calcitonin receptors to slow gastric emptying, reduce post-meal glucagon, and signal satiety. Half-life ~7 days, supporting weekly dosing. Read the full Cagrilintide explainer →

Semaglutide, the GLP-1 component

The active ingredient in Ozempic, Wegovy, and Rybelsus. Acts on GLP-1 receptors to suppress appetite, slow gastric emptying, and stimulate glucose-dependent insulin secretion. Half-life ~7 days. The most-prescribed GLP-1 drug in the world. Read the full Semaglutide explainer →

Mechanism of the combination

The case for combining cagrilintide and semaglutide rests on additive appetite suppression through complementary pathways:

  • Cagrilintide (amylin pathway): slows gastric emptying, reduces post-meal glucagon, signals satiety via the area postrema and other CNS regions.
  • Semaglutide (GLP-1 pathway): slows gastric emptying, suppresses appetite via GLP-1 receptors in the hypothalamus, stimulates glucose-dependent insulin secretion.
  • Combined: two complementary appetite-related mechanisms hitting at once. Phase 1b/2 data showed the combination produced greater weight loss than either alone, additive rather than redundant.

Both peptides have ~7-day half-lives, supporting once-weekly fixed-dose combination administration.

The REDEFINE Phase 3 program

REDEFINE-1, chronic weight management (without diabetes)

Phase 3 randomized trial in adults with overweight or obesity but without diabetes. CagriSema produced about 22.7% mean weight loss over 68 weeks. Below Novo's previously-guided 25% expectation; competitive with tirzepatide's SURMOUNT-1 result (22.5% over 72 weeks).

REDEFINE-2, type 2 diabetes

Phase 3 trial in adults with T2D and overweight/obesity. A1C and weight outcomes specific to that population.

REDEFINE-3 and beyond

Additional Phase 3 readouts in different patient subgroups continue to publish through 2025 and 2026.

Cardiovascular outcomes

Long-term cardiovascular outcomes trials are part of the broader development program.

Side effects and safety profile

The most common adverse events in trials have been gastrointestinal, nausea, vomiting, decreased appetite, constipation. The side-effect profile has not been notably worse than semaglutide alone, which is meaningful, adding the amylin component appears not to substantially worsen tolerability.

Discontinuation rates due to adverse events have been broadly comparable to semaglutide.

Boxed warning class effects (thyroid C-cell tumors observed in rodent studies for the GLP-1 class) are expected to apply.

Long-term safety data continues to accumulate through the REDEFINE program and into post-approval surveillance once approved.

References

  1. Novo Nordisk. "REDEFINE-1 Phase 3 results." Press release December 2024. Novo Nordisk
  2. Novo Nordisk. "REDEFINE-2 Phase 3 results in type 2 diabetes." Press releases 2024–2025.
  3. Enebo LB, Berthelsen KK, Kankam M, et al. (2021). "Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial." The Lancet, 397(10286), 1736–1748. PubMed
  4. ClinicalTrials.gov. REDEFINE program registry. ClinicalTrials.gov
For educational and research purposes only. This is not medical advice. CagriSema is investigational and not FDA-approved as of May 2026. Compounded versions are not the FDA-approved drug. PeptideLibraryHub is independent and does not sell peptides or accept money from anyone who does.